On Sept. 7, 2020, Pfizer and BioNTech announced that the German regulatory authority, the Paul-Ehrlich-Institut, had approved the Phase 2/3 clinical trial in Germany for their BNT162b2 vaccine candidate. The placebo-controlled trial evaluated the safety and efficacy of BNT162b2 in up to 30,000 participants between 18 and 85 years of age.